GeorgeLiweiChenMD
Hematology • Houston, TXHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Roswell Park Cancer Institute
Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-1782
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004- Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
The University of Texas Health Science Center at San AntonioClass of 1998
Certifications & Licensure
CA State Medical License 2002 - Present
FL State Medical License 2024 - Present
AZ State Medical License 2024 - 2027
TN State Medical License 2024 - 2026
TX State Medical License 2000 - 2026
AL State Medical License 2024 - 2025
GA State Medical License 2024 - 2025- American Board of Internal Medicine Hematology
- Join now to see all
Clinical Trials
- Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease Start of enrollment: 2010 Aug 01
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Start of enrollment: 2013 Mar 01
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host Disease.Betty K Hamilton, Lynn Onstad, Paul A Carpenter, Joseph Pidala, Najla El Jurdi
Contemporary Clinical Trials. 2024-10-01 - Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation.Joseph A Pidala, Lynn Onstad, Emily Baumrin, Paul A Carpenter, Corey Cutler
Blood Advances. 2024-09-10 - 3 citationsGalectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.Philip L McCarthy, Kristopher M Attwood, Xiaojun Liu, George L Chen, Hans Minderman
Bone Marrow Transplantation. 2024-03-01
Abstracts/Posters
- _2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia EffectGeorge L. Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...George L. Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Phase III SIERRA Trial Finds Iomab-B Promising for Relapsed/Refractory AMLApril 8th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
